News
Higher Dairy Intake May Up Risk for Prostate Cancer
However, association does not hold for nondairy calcium intake
Your search for prostate returned 35 results
Drugs in the Pipeline
Darolutamide Plus Docetaxel Gets Priority Review for Metastatic Hormone-Sensitive Prostate Cancer
The sNDA is supported by data from the phase 3 ARASENS trial, which included1306 patients with mHSPC.
News
Camcevi Now Available for Advanced Prostate Cancer Treatment
Camcevi is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, a gonadotropin-releasing hormone agonist.
News
Pluvicto Approved for PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Pluvicto is a radioligand therapeutic agent containing the active moiety, lutetium-177, which binds to PSMA, a transmembrane protein that is expressed in prostate cancer.
Drugs in the Pipeline
Merck Halts Trial Evaluating Combo Therapy for Metastatic Castration-Resistant Prostate Cancer
Following a planned interim analysis, the decision to halt the trial was made after a review of data by an independent Data Monitoring Committee.
ASCO GU 2022
Niraparib With Abiraterone + Prednisone Improves Outcomes in HRR BM+ Metastatic Castration Resistant Prostate Cancer
The phase 3 MAGNITUDE study assessed niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC with or without alterations in homologous recombination repair associated genes.
ASCO GU 2022
Relugolix Effective, Safe in Black Men With Advanced Prostate Cancer
Study authors analyzed a total of 46 Black men with advanced prostate cancer enrolled in the phase 3 HERO study.
News
Adding ADT to Radiotherapy Ups Mets-Free Survival in Prostate Cancer
In meta-analysis, adjuvant ADT prolongation also linked to improvement in metastasis-free survival, but not neoadjuvant ADT extension
News
Nonselective Beta-Blockers May Reduce Prostate Cancer Recurrence Risk
The perioperative period is receiving increased attention as a platform to inhibit cancer progression, according to investigators.
News
Prostate Cancer ADT Has Fewer Cardiovascular Risks Than Expected
Investigators found that men receiving androgen deprivation therapy for prostate cancer had a 1% rate of major adverse cardiovascular events.
